Capital International Investors Invests $53.01 Million in NewAmsterdam Pharma (NASDAQ:NAMS)

Capital International Investors acquired a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,062,535 shares of the company's stock, valued at approximately $53,007,000. Capital International Investors owned 2.23% of NewAmsterdam Pharma at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in NAMS. Jennison Associates LLC boosted its holdings in shares of NewAmsterdam Pharma by 291.9% during the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after acquiring an additional 2,978,263 shares during the period. Wellington Management Group LLP boosted its stake in NewAmsterdam Pharma by 2,410.4% during the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after purchasing an additional 2,222,900 shares during the period. Alliancebernstein L.P. bought a new position in NewAmsterdam Pharma in the 4th quarter worth about $47,752,000. TimesSquare Capital Management LLC raised its holdings in shares of NewAmsterdam Pharma by 250.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company's stock valued at $23,016,000 after buying an additional 640,329 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $8,907,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

NAMS traded up $0.05 on Friday, reaching $17.52. 345,323 shares of the company traded hands, compared to its average volume of 592,501. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -6.74 and a beta of -0.01. The stock's 50 day moving average price is $19.61 and its 200-day moving average price is $21.19.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to the consensus estimate of $3.30 million. As a group, equities research analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James N. Topper purchased 1,135 shares of the firm's stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the transaction, the director now directly owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 19.50% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on NAMS. HC Wainwright reissued a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Royal Bank of Canada restated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Finally, Scotiabank increased their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.